Showing results (1-10 of 135) with videos related to
Sort By:
Pageof 14
International Journal of Cancer|August 29, 2013
Anti-CD73 therapy impairs tumor angiogenesisBertrand Allard, Martin Turcotte, Kathleen Spring, et al.Cancer Research|November 23, 2016
PolyI:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint InhibitorsRoxanne Charlebois, Bertrand Allard, David Allard, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 29, 2013
Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbsBertrand Allard, Sandra Pommey, Mark J Smyth, et al.Expert Opinion on Therapeutic Targets|May 7, 2014
Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancerBertrand Allard, Martin Turcotte, John StaggJournal of Biomedicine & Biotechnology|November 6, 2012
CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growthBertrand Allard, Martin Turcotte, John StaggMethods in Enzymology|November 16, 2019
Measurement of CD73 enzymatic activity using luminescence-based and colorimetric assaysBertrand Allard, Isabelle Cousineau, Kathleen Spring, et al.Oncoimmunology|July 29, 2016
CD73-adenosine reduces immune responses and survival in ovarian cancer patientsPierre-Olivier Gaudreau, Bertrand Allard, Martin Turcotte, et al.Oncoimmunology|August 16, 2019
Adenosine A2a receptor promotes lymphangiogenesis and lymph node metastasisBertrand Allard, Isabelle Cousineau, David Allard, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 9, 2015
CD73 Expression Is an Independent Prognostic Factor in Prostate CancerBruno G Leclerc, Roxanne Charlebois, Guillaume Chouinard, et al.Therapeutic Advances in Medical Oncology|May 2, 2013
Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospectsJohn Stagg, Bertrand AllardPageof 14